Collegium Pharmaceutical (NasdaqGS:COLL) M&A announcement Transcript

Summary of Collegium Pharmaceutical Investor Call Company Overview - Company: Collegium Pharmaceutical (NasdaqGS: COLL) - Industry: Biopharmaceuticals, specifically focusing on ADHD and pain management Key Points from the Call Acquisition Announcement - Collegium announced the acquisition of AZSTARYS and relevant corporate subsidiaries from Corium Therapeutics for $650 million in cash, with potential contingent payments of up to $135 million based on sales and regulatory milestones [2][8][19] - This acquisition significantly expands Collegium's position in the ADHD market, complementing its existing product Jornay PM [2][5] Strategic Rationale - The acquisition is seen as a strategic addition that accelerates growth and enhances patient care, with a focus on differentiated commercial medicines that have exclusivity into the 2030s and beyond [4][5] - AZSTARYS is expected to extend future ADHD revenues into 2037, five years beyond Jornay PM's expected loss of exclusivity [7][19] Financial Implications - The acquisition is expected to be immediately accretive to adjusted EBITDA, with AZSTARYS projected to generate over $50 million in pro forma net revenues in the second half of 2026 [10][11] - Collegium generated over $329 million in cash from operations in 2025, indicating strong cash flow to support the acquisition [9] Market Dynamics - The ADHD market is large and growing, with approximately 22 million patients in the U.S. and 111 million prescriptions written in 2025 [12] - Prescriptions for ADHD have been growing at about 8% annually over the past five years, with 90% of prescriptions for stimulant medications [12] Product Differentiation - Jornay PM is unique as it is taken at night and provides efficacy upon awakening, while AZSTARYS combines fast and long-acting medications in one capsule, addressing different patient needs [15][17] - Both products are expected to be complementary, with 70% of healthcare professionals indicating a strong intent to increase prescribing of Jornay PM and 53% for AZSTARYS [15][16] Operational Synergies - Collegium plans to leverage its existing ADHD commercial infrastructure to achieve significant cost synergies, estimated to exceed $50 million within 12 months post-acquisition [10] - The combined sales force will enhance market access and operational efficiencies, allowing for better service to the ADHD community [18] Future Outlook - Collegium remains focused on executing its strategy of driving growth through business development, with an openness to exploring other therapeutic areas, including rare diseases [49][50] - The company plans to update its financial guidance for 2026 following the transaction's closure, expected in the second quarter [11][19] Additional Insights - The acquisition aligns with Collegium's capital allocation strategy, balancing portfolio expansion with fiscal responsibility [8] - The company emphasizes its commitment to improving patient care and delivering shareholder value through strategic acquisitions and operational efficiencies [21][22]